FDA Advisory Committee Votes in Favor of Pfizers MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia

14th July 2017 Uncategorised 0

Pfizer

More: FDA Advisory Committee Votes in Favor of Pfizers MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia
Source: MDlinx